Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConduit Hldg Regulatory News (CRE)

Share Price Information for Conduit Hldg (CRE)

Share Price is delayed by 15 minutes
Get Live Data
445.00    8.50 (1.95%)
Bid:
444.50
Ask:
445.00
Spread: 0.50 (0.112%)
Market Cap: £658.17m
CRE Live PriceLast checked at - London Stock Exchange

Intraday Conduit Hldg Share Chart

Trading Statement

20 Apr 2011 07:00

RNS Number : 2169F
Creston PLC
20 April 2011
Β 

ο»Ώ

Β 

Β 

Β 

Β 

Β 

Β 

20 April 2011Β 

Β 

Β 

Creston plc

Pre-Close Trading Statement

Β 

Creston plc ("Creston" or the "Group"; LSE: CRE), the Insight and Communications Group, provides an update on trading in advance of the preliminary results announcement for the year ended 31 March 2011.

Β 

In its 2011 financial year, the Group has performed in line with the Board's expectations driven by revenue growth on a continuing group basis of 11 per cent, or 7 per cent on a like-for-like basis, which represents a strong performance versus the sector. This growth has been driven by organic growth from existing clients, as well as some exciting new client wins.

Β 

The second half of the year reported growth in revenue, operating profit and margin compared to the first half and ended with a like-for-like revenue growth of 10 per cent in the final quarter.

Β 

The first three months' trading for the recently acquired Cooney/Waters and Alembic Health businesses has exceeded the Board's expectations, whilst their integration is making good progress under the newly appointed CFO.

Β 

Operating cash flow has been ahead of the Board's expectations, resulting in a broadly debt free position at the year end. At 18 April 2011 the Group had net cash of Β£2.6 million. This positive cash position is after paying the initial cash consideration of Β£5.9 million for Cooney/Waters and Alembic Health in December 2010.

Β 

Creston expects to announce its preliminary results for the year ended 31 March 2011 on Tuesday, 21 June 2011.

Β 

Β 

Β 

-Ends-

Β 

Enquiries:

Β 

Creston plc

www.creston.com

Don Elgie, Chief Executive

020 7930 9757

Barrie Brien, COO/CFO

Β 

Sarah Macleod, Communications Director

Β 

Β 

Β 

Investec Bank Plc

David Flin /Carlton Nelson

Β 

020 7597 5970

Β 

NOTES TO EDITORS:

Β 

Β§ Publication quality photographs are available on www.creston.com.

Β 

About Creston plc

Β 

Β§ Creston is an Insight and Communications company for the 21st century. It offers clients more seamless access to the most innovative marketing insights and communications services to help grow their brands in a rapidly-changing consumer world. Our companies draw upon the collective knowledge, expertise and services from across-the-Group, so that their clients receive the best advice and achieve the best results no matter what the medium. By working together, whether on research or as full-scale marketing partners, our companies continuously innovate to make more things possible for their clients and people.

Β 

Β§ Creston companies offer a range of marketing services, such as, market research, direct and digital marketing, public relations, advertising and healthcare marketing to a broad range of blue-chip clients including: Astellas, AstraZeneca, Aviva, BMW, BT, Canon, COI Communications, Danone, Diageo, GlaxoSmithKline, HTC,Β Jaguar, Land Rover, Lexus, Nissan, Pfizer, Roche, Sainsbury's, Sanofi Pasteur, Sony Europe, Tesco, Toshiba, T-Mobile, Tropicana, Unilever, Vodafone and Walkers.

Β 

Β§ Creston's share price is quoted in the Financial Times, The Daily Telegraph, The Times and the London Evening Standard.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTGGUMPCUPGGQB
Date   Source Headline
27th Jun 20113:11 pmRNSHolding(s) in Company
23rd Jun 20113:59 pmRNSHolding(s) in Company
23rd Jun 201112:40 pmRNSHolding(s) in Company
21st Jun 20113:21 pmRNSHolding(s) in Company
21st Jun 20117:00 amRNSFinal Results
20th Jun 20115:46 pmRNSHolding(s) in Company
10th Jun 20117:00 amRNSDirectorate Change
10th May 20119:59 amRNSAnnual Information Update
10th May 20117:00 amRNSInvestor & Analyst Presentation
20th Apr 20117:00 amRNSTrading Statement
13th Apr 201112:14 pmRNSHolding(s) in Company
7th Apr 20114:02 pmRNSHolding(s) in Company
17th Feb 20112:28 pmRNSHolding(s) in Company
16th Feb 20112:21 pmRNSHolding(s) in Company
16th Feb 201112:39 pmRNSHolding(s) in Company
3rd Feb 20117:00 amRNSInterim Management Statement
5th Jan 20113:10 pmRNSNotice of Interim Management Statement
22nd Dec 20109:56 amRNSCompletion of Acquisition
15th Dec 201012:40 pmRNSResult of Meeting
30th Nov 20107:00 amRNSInterim Results
30th Nov 20107:00 amRNSAcquisition
8th Nov 20102:18 pmRNSHolding(s) in Company
19th Oct 20101:09 pmRNSHolding(s) in Company
19th Oct 20101:07 pmRNSHolding(s) in Company
11th Oct 201011:12 amRNSNotice of Interim Results
28th Sep 20108:00 amRNSCreation of E-Healthcare Start-Up
2nd Sep 201010:55 amRNSAGM Statement
26th Jul 20107:00 amRNSInterim Management Statement
14th Jul 20104:12 pmRNSDirector/PDMR Shareholding
14th Jul 201011:54 amRNSDisposal
13th Jul 20109:51 amRNSResult of General Meeting
28th Jun 20104:30 pmRNSPosting of Circular
28th Jun 201010:35 amRNSHolding(s) in Company
28th Jun 20107:01 amRNSDisposal
28th Jun 20107:00 amRNSFinal Results
26th May 20104:52 pmRNSHolding(s) in Company
26th May 20108:40 amRNSNotice of Results
21st May 201012:56 pmRNSHolding(s) in Company
13th May 20105:46 pmRNSHolding(s) in Company
26th Apr 20102:13 pmRNSHolding(s) in Company
22nd Apr 20103:05 pmRNSHolding(s) in Company
20th Apr 20107:00 amRNSPre-Close Trading Statement
6th Apr 20104:29 pmRNSDirector/PDMR Shareholding
6th Apr 20104:26 pmRNSDirector/PDMR Shareholding
23rd Mar 20104:50 pmRNSDirector/PDMR Shareholding
23rd Mar 20104:41 pmRNSDirector/PDMR Shareholding
17th Feb 20105:51 pmRNSHolding(s) in Company
3rd Feb 20107:00 amRNSInterim Management Statement
10th Dec 20097:33 amRNSDirector/PDMR Shareholding
2nd Dec 20097:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.